Under normal circumstances, the immune system recognises and successfully fights cancer cells, eliminating them as they develop.

However, sometimes the process breaks down and tumours form, and now we know why.

Researchers at the Texas A&M Health Science Center found that when cancer cells are able to block the function of a gene called NLRC5, they are able to evade the immune system and proliferate, according to research published in the Proceedings of the National Academy of Sciences.

“We found the major mechanism of how cancer cells escape from our immune system and form tumours,” said Koichi Kobayashi, M.D., Ph.D., professor at the Texas A&M College of Medicine and a lead author on the PNAS article.

The discovery indicates NLRC5 as a novel biomarker for cancer patient survival and therapeutic response, as well as a potential target for new treatments.

“Cancer cells are born because of genetic changes, such as mutations or rearrangement of pieces of different chromosomes,” Kobayashi said. “Because of this, all cancer cells have new, ‘foreign’ genes, which host T-cells generally detect as tumour antigens. This anti-tumour system works very well.”

Kobayashi and his colleagues discovered several years ago that NLRC5 regulates major histocompatibility complex (MHC) class I genes.

These genes code for molecules on the surface of cells that present fragments of foreign proteins—such as those from a virus or bacterium— that have invaded the cell.

These fragments notify a part of the immune system called cytotoxic T cells, triggering an immediate response from the immune system against that particular foreign antigen.

The novel finding in this study is that the same system should work to destroy cancer cells, but sometimes they find a way to disable the NLRC5 gene, thus enabling them to evade the immune system and form tumours.

“If MHC class I antigen presentation does not work, cancer cells will not be killed by T cells,” said Sayuri Yoshihama, M.D., Ph.D., a fellow in Kobayashi’s lab and first author of the paper. “We found that function and expression of NLRC5 is reduced in cancer cells by various mechanisms, and the result is immune evasion by cancer cells.”

In fact, based on biopsy samples from 7,747 solid cancer patients in The Cancer Genome Atlas (TCGA) database, expression of this NLRC5 gene is highly correlated with cancer patient survival in various cancer types—especially melanoma, rectal cancer, bladder cancer, cervical cancer and head/neck cancer—with patients who survive longer tending to have greater expression of NLRC5.

Among these, melanoma and bladder cancer displayed the most striking differences, with 5-year survival rates of 36 percent and 34 percent in the NLRC5-low expression group compared with 71 percent and 62 percent in the NLRC5-high expression group, respectively.

“With this finding of NLRC5 as an important biomarker for cancer, we can ultimately predict how long cancer patients can survive and how well cancer treatments might work for them,” Kobayashi said.

It might be especially relevant for melanoma patients, both because NLRC5 mutation rate is relatively high and because its levels of expression are highly predictive of survival for that cancer type.

The team plans to continue its research on the role of NLRC5 in cancer and is actively developing plans for commercialisation of technology related to this discovery.

A provisional patent application has been filed, and plans are underway to develop and validate a test that can, based on NLRC5 expression levels, be used to predict cancer patient survival and therapeutic response.

The hope is that the test will give health care providers one more tool for determining the best treatment strategy for cancer patients to eliminate the burden of costly, unhelpful therapies.

Eventually, Kobayashi and his team hope this discovery might also lead to new therapeutic strategies for cancer.
“If we can regulate the activation of NLRC5 or its expression level, that could be a novel cancer treatment,” Kobayashi said. “We hope that in several years, our research may identify potential drug candidates that can increase the levels of NLRC5 and thus help our own immune systems better fight the cancer.”

Still, he advises caution.

This mechanism of evading the immune system is not employed by every cancer cell, and the research still needs to be replicated in an animal model.

Cancer isn’t the only surprising disease that can be affected by the immune system.

Kobayashi’s previous work in immune function and genetics focused on inflammatory bowel disease, such as Crohn’s disease.

They also study transplant medicine, trying to determine why some organs are rejected by the new host.

“We now know why cancer cells can escape from our immune system,” Kobayashi said. “No other mechanism is as dramatic as we found. We envision the NLRC5 biomarker as allowing physicians to evaluate and determine the best treatment strategy for each cancer patient, thus leading to better therapeutic outcomes for the more than 12 million people diagnosed with cancer each year.”

Source: PNAS